Literature DB >> 10636413

Utility values and age-related macular degeneration.

G C Brown1, S Sharma, M M Brown, J Kistler.   

Abstract

OBJECTIVE: To ascertain the utility values associated with age-related macular degeneration and varying degrees of visual loss.
DESIGN: A cross-sectional study. PARTICIPANTS: Eighty white patients with unilateral or bilateral age-related macular degeneration in 1 or both eyes, and visual loss to a minimum of the 20/40 level in at least 1 eye. MAIN OUTCOME MEASURES: Utility values were measured in 5 groups according to the visual acuity in the better-seeing eye, 1 (20/20 to 20/25), 2 (20/30 to 20/ 50), 3 (20/60 to 20/100), 4 (20/200 to 20/400), and 5 (counting fingers to light perception), using the time trade-off and the standard gamble methods. Conventionally assigned anchor utility values were 1.0 for perfect health and 0.0 for death.
RESULTS: The mean utility value for the total group with age-related macular degeneration was 0.72 (95% confidence interval [CI], 0.66-0.78) using the time trade-off method and 0.81 (95% CI, 0.76-0.86) using the standard gamble method. Using the time trade-off method correlated with the visual acuity in the better-seeing eye, the results were as follow: group 1, 0.89 (95% CI, 0.82-0.96), group 2, 0.81 (95% CI, 0.73-0.89), group 3, 0.57 (95% CI, 0.47-0.67), group 4, 0.52 (95% CI, 0.38-0.66), and group 5, 0.40 (95% CI, 0.29-0.50). Thus, those patients in group 1 were willing to trade 11% of their remaining lifetime in return for perfect vision in each eye, whereas those in group 5 were willing to trade 60% of their remaining lifetime in return for perfect vision in each eye.
CONCLUSION: Age-related macular degeneration causes a substantial decrease in patient utility values and is highly dependent on the degree of visual loss in the better-seeing eye.

Entities:  

Mesh:

Year:  2000        PMID: 10636413     DOI: 10.1001/archopht.118.1.47

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  72 in total

1.  The reproducibility of ophthalmic utility values.

Authors:  G C Brown; M M Brown; S Sharma; G Beauchamp; H Hollands
Journal:  Trans Am Ophthalmol Soc       Date:  2001

2.  Ophthaproblem. Vitamin supplementation.

Authors:  Sanjay Sharma; Gaurav K Shah
Journal:  Can Fam Physician       Date:  2002-03       Impact factor: 3.275

3.  Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients.

Authors:  S Sharma; G C Brown; M M Brown; H Hollands; R Robins; G K Shah
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

4.  Ophthaproblem. Photodynamic therapy with verteporfin.

Authors:  S Sharma
Journal:  Can Fam Physician       Date:  2001-05       Impact factor: 3.275

5.  A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes.

Authors:  M M Brown; G C Brown; S Sharma; A F Smith; J Landy
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

6.  Impact of photodynamic therapy on quality of life of patients with age-related macular degeneration in Korea.

Authors:  Jinhyun Kim; Hyung Woo Kwak; Won Ki Lee; Ha Kyoung Kim
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

Review 7.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

Review 8.  Economic cost of age-related macular degeneration: a review of recent research.

Authors:  Kathleen M Ke; Usha Chakravarthy; Ciaran O'Neill
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

9.  Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.

Authors:  Meidong Zhu; Wijeyanthy Wijeyakumar; Adil R Syed; Nichole Joachim; Thomas Hong; Geoffrey K Broadhead; Haitao Li; Kehui Luo; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-30       Impact factor: 3.117

10.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.